Roaring Aesica Eyes Growth in the U.S.
Aesica isn't the only one, others are hiring in the U.S.! Check it out! (Isn't it tempting?)
Pharmacautical giant Aesica is poised for significant expansion through a growth plan which entails establishing further presence overseas, further acquisitions and the £30m investment in a new manufacturing unit. Since leading the 2004 management buyout of BASF’s production facility in Cramlington, Dr Robert Hardy has steered the firm through rapid growth, changing the company’s core focus which has resulted in it increasing turnover and staffing levels tenfold. From an initial 130 members of staff, it now has a 1,300 strong workforce at six development and manufacturing sites across Europe in the UK, Germany and Italy, and an extra 100 jobs are now being created at its secondary manufacturing facility, at Queenborough in Kent, where a new £30m unit opens next month.
Don't forget, hundreds of biopharma companies are hiring! (We know you can't resist.)
Pharmacautical giant Aesica is poised for significant expansion through a growth plan which entails establishing further presence overseas, further acquisitions and the £30m investment in a new manufacturing unit. Since leading the 2004 management buyout of BASF’s production facility in Cramlington, Dr Robert Hardy has steered the firm through rapid growth, changing the company’s core focus which has resulted in it increasing turnover and staffing levels tenfold. From an initial 130 members of staff, it now has a 1,300 strong workforce at six development and manufacturing sites across Europe in the UK, Germany and Italy, and an extra 100 jobs are now being created at its secondary manufacturing facility, at Queenborough in Kent, where a new £30m unit opens next month.
Don't forget, hundreds of biopharma companies are hiring! (We know you can't resist.)